Oseltamivir Pharmacokinetics in Morbid Obesity

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Morbid Obesity
Interventions
OTHER

Patients with a BMI < 30 given Oseltamivir

Patients with a BMI \< 30 given Oseltamivir

OTHER

Patients with a BMI > 40 given Oseltamivir

Patients with a BMI \> 40 given Oseltamivir

Trial Locations (1)

B3K 6R8

Human Vaccine Challenge Unit, IWK Health Center, Halifax

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Canadian Center for Vaccinology

OTHER

collaborator

Nova Scotia Health Authority

OTHER

collaborator

Dalhousie University

OTHER

collaborator

Hoffmann-La Roche

INDUSTRY

lead

IWK Health Centre

OTHER